FGI-104
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| PubChem (CID) | 44158960 |
| Chemical and physical data | |
| Formula | C28H30ClN3O3 |
| Molar mass | 492.008 |
| 3D model (Jmol) | Interactive image |
| |
FGI-104 is the name for a family of chemical compounds that act as broad-spectrum antiviral drugs, with activity against a range of viruses including Hepatitis B, Hepatitis C, HIV, Ebola virus and Venezuelan equine encephalitis virus. Compound R19 is the most preferred compound listed in the patent covering this family.[1][2][3]
Mechanism
The FGI-104 family of compounds act by inhibiting the protein TSG101, which transports newly replicated viruses to the exterior of an infected cell, and is required by many viruses to reinfect other cells. In pre-clinical studies FGI-104 has been shown to protect mice from Ebola virus disease.[1][4]
See also
References
- 1 2 http://www.ajtr.org/812004A.html Jan 2009 "FGI-104: A Broad-Spectrum Small Molecule Inhibitor of Viral Infection"
- ↑ Michael Kinch, Michael Goldblatt. Methods of inhibiting viral infection. Patent WO 2009/091435
- ↑ De Clercq E. "A Cutting-Edge View on the Current State of Antiviral Drug Development." Med Res Rev. 2013 Mar 11. doi: 10.1002/med.21281. PubMed link
- ↑ Janeba Z. Development of Small-Molecule Antivirals for Ebola. Medicinal Research Reviews November 2015, 35(6):1175-1194. doi: 10.1002/med.21355
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the 8/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.